High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Evangelos Terpos, Meletios A. Dimopoulos, Vikas Shrivastava, Kim Leitzel, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Konstantinos Anargyrou, Peter Hamer, Efstathios Kastritis, Walter Carney, Allan Lipton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.

Original languageEnglish (US)
Pages (from-to)399-402
Number of pages4
JournalLeukemia Research
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Tissue Inhibitor of Metalloproteinase-1
Multiple Myeloma
Survival
Serum
Bone Diseases
Bone Resorption
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Terpos, Evangelos ; Dimopoulos, Meletios A. ; Shrivastava, Vikas ; Leitzel, Kim ; Christoulas, Dimitrios ; Migkou, Magdalini ; Gavriatopoulou, Maria ; Anargyrou, Konstantinos ; Hamer, Peter ; Kastritis, Efstathios ; Carney, Walter ; Lipton, Allan. / High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. In: Leukemia Research. 2010 ; Vol. 34, No. 3. pp. 399-402.
@article{159eb40365b741f4ac9d23a255fb2184,
title = "High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents",
abstract = "Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47{\%} of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.",
author = "Evangelos Terpos and Dimopoulos, {Meletios A.} and Vikas Shrivastava and Kim Leitzel and Dimitrios Christoulas and Magdalini Migkou and Maria Gavriatopoulou and Konstantinos Anargyrou and Peter Hamer and Efstathios Kastritis and Walter Carney and Allan Lipton",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.leukres.2009.08.035",
language = "English (US)",
volume = "34",
pages = "399--402",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",

}

Terpos, E, Dimopoulos, MA, Shrivastava, V, Leitzel, K, Christoulas, D, Migkou, M, Gavriatopoulou, M, Anargyrou, K, Hamer, P, Kastritis, E, Carney, W & Lipton, A 2010, 'High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents', Leukemia Research, vol. 34, no. 3, pp. 399-402. https://doi.org/10.1016/j.leukres.2009.08.035

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. / Terpos, Evangelos; Dimopoulos, Meletios A.; Shrivastava, Vikas; Leitzel, Kim; Christoulas, Dimitrios; Migkou, Magdalini; Gavriatopoulou, Maria; Anargyrou, Konstantinos; Hamer, Peter; Kastritis, Efstathios; Carney, Walter; Lipton, Allan.

In: Leukemia Research, Vol. 34, No. 3, 01.03.2010, p. 399-402.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

AU - Terpos, Evangelos

AU - Dimopoulos, Meletios A.

AU - Shrivastava, Vikas

AU - Leitzel, Kim

AU - Christoulas, Dimitrios

AU - Migkou, Magdalini

AU - Gavriatopoulou, Maria

AU - Anargyrou, Konstantinos

AU - Hamer, Peter

AU - Kastritis, Efstathios

AU - Carney, Walter

AU - Lipton, Allan

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.

AB - Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.

UR - http://www.scopus.com/inward/record.url?scp=77649187602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649187602&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.08.035

DO - 10.1016/j.leukres.2009.08.035

M3 - Article

C2 - 19781774

AN - SCOPUS:77649187602

VL - 34

SP - 399

EP - 402

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -